|
|
 |
International Clinical Trials in Oncology
Albania
Algeria
Argentina
- Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
Buenos Aires; Hospital Britanico De Buenos Aires
- Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
Buenos Aires; Corporacion Medica De General San Martin
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Buenos Aires ; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Cordoba; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
La Plata; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Mar Del Plata; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Mendoza; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
San Martin; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Santa Fe; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Buenos Aires ; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Córdoba; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
La Plata; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Mar Del Plata; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Rosario; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Tucuman; Research Site:
- Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Buenos Aires ; Research Site:
- Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Chaco-Resistencia; Research Site:
- Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Córdoba; Research Site:
- Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
La Plata; Research Site:
- Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Mendoza; Research Site:
- Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Rosario; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Buenos Aires ; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Rosario; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Buenos Aires ; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Bahia Blanca; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Buenos Aires ; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Córdoba; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
La Plata; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Rosario; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Salta; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
San Miguel De Tucuman; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Santa Fe; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Buenos Aires ; Research Site:
- Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
Buenos Aires ; Research Site:
- Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
Rosario; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
Buenos Aires ; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
Córdoba; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
La Plata; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
Pilar; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
Rosario; Research Site:
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
La Plata; Instituto Medico Platense
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Provincia de Buenos Aires; Instituto Medico
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Provincia de Santa Fe, Santa Fe; ISIS Clinica Especializada
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Buenos Aires; Hospital General de Agudos Carlos G. Durand
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Buenos Aires; Hospital Britanico de Buenos Aires
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Buenos Aires; Hospital Militar Central
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Buenos Aires; Hospital Municipal de Oncologia Maria Curie
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Cordoba; Hospital Privado de Cordoba S.A.
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
Buenos Aires ; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin's Lymphoma
La Plata; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Bahia Blanca; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Buenos Aires ; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Córdoba; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Corrientes; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
La Plata; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Buenos Aires ; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Chaco-Resistencia; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Córdoba; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Tucuman; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Bahia Blanca; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Buenos Aires ; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Mendoza; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
San Miguel De Tucuman; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Santa Fe; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Buenos Aires ; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Córdoba; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
La Plata; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Salta; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Santa Fe; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Rosario; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
San Martín; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Villa Domínico; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Buenos Aires ; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Santa Fe; Research Site:
- Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Buenos Aires; Instituto Médico Especializado Alexander Fleming
- Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Cordoba; Instituto Oncologico De Cordoba
- Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Santa Fe; Isis Clinica Especializada
Australia
- Bladder Cancer: A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Adelaide, South Australia; Research Site
- Bladder Cancer: A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Sydney, New South Wales; Research Site
- Bladder Cancer: A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Waratah, New South Wales; Research Site
- Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
Brisbane; Research Site:
- Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
Fitzroy; Research Site:
- Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
Geelong; Research Site:
- Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
Liverpool; Research Site:
- Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
Parkville; Research Site:
- Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
Waratah; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Fitzroy; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Geelong; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Lismore; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Nambour; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Perth; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Port Macquarie; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Sydney; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Waratah; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Wollongong; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
Adelaide; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
Brisbane; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
Fitzroy; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
Melbourne; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
Perth; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
Sydney; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Adelaide; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Brisbane; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Darlinghurst; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
East Melbourne; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Frankston; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Gosford; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Lismore; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Maroochydore; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Perth; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Richmond; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
St. Leonards; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Sydney; Research Site:
- Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
Wodonga; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Adelaide; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Brisbane; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Fitzroy; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Frankston; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Heidelberg; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Hobart; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Malvern; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Melbourne; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Parkville; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Perth; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Sydney; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Waratah; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Wodonga; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
Adelaide; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
Geelong; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
Melbourne; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
Perth; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
Southport; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
Sydney; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Geelong; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
Brisbane; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
Geelong; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
Parkville; Research Site:
- Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
Perth; Research Site:
- Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
Geelong; Research Site:
- Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
Perth; Research Site:
- Breast Cancer: A Study of Pertuzumab in Patients With Metastatic Breast Cancer
Fitzroy; Research Site:
- Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Waratah; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Adelaide; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Brisbane; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Fitzroy; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Geelong; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Heidelberg; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Malvern; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Melbourne; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Nambour; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Parkville; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Perth; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Port Macquarie; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
St. Leonards; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Sydney; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Waratah; Research Site:
- Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Wollongong; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Adelaide; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Fitzroy; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Frankston; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Geelong; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Heidelberg; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Liverpool; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Melbourne; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Parkville; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Perth; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Sydney; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Toowoomba; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Waratah; Research Site:
- Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
Wodonga; Research Site:
- Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Adelaide; Research Site
- Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Freemantle; Research Site
- Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Gosford; Research Site
- Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Nedlands; Research Site
- Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
St. Leonards; Research Site
- Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Waratah; Research Site
- Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Westmead; Research Site
- Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Woodville; Research Site
- Chronic Lymphocytic Leukemia: Lumiliximab with Fludarbine, Cyclophosphamide and Rituximab (FCR) Versus FCR Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL)
Woolloongabba; Research Site
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Adelaide; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Brisbane; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Fitzroy; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Malvern; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Melbourne; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Perth; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Sydney; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
Wollongong; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Adelaide; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Adelaide; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Brisbane; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Brisbane; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Darlinghurst; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Fremantle; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Heidelberg; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Kingswood; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Melbourne; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Melbourne; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Perth; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Port Macquarie; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
St. Leonards; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Sydney; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Sydney; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Waratah; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Waratah; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
Wodonga; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Fitzroy; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Melbourne; Research Site:
- Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Sydney; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Adelaide; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Brisbane; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Fitzroy; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Malvern; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Melbourne; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Perth; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Port Macquarie; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
St. Leonards; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
Sydney; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Adelaide; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Bendigo; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Brisbane; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Fitzroy; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Melbourne; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Perth; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Port Macquarie; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
St. Leonards; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Sydney; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Wodonga; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Adelaide; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Melbourne; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Perth; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Port Macquarie; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Sydney; Research Site:
- Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
Wollongong; Research Site:
- Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
Adelaide; Research Site:
- Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
Heidelberg; Research Site:
- Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
Melbourne; Research Site:
- Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
Sydney; Research Site:
- Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Adelaide; Research Site:
- Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Brisbane; Research Site:
- Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Melbourne; Research Site:
- Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Perth; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Adelaide; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Brisbane; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Fitzroy; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Frankston; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Fremantle; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Geelong; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Gosford; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Liverpool; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Melbourne; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Newcastle; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Perth; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
St. Leonards; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Sydney; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Waratah; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Wodonga; Research Site:
- Lymphocytic Leukemia, Chronic: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.
Woolloongabba; Research Site:
- Lymphocytic Leukemia, Chronic: A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Frankston; Research Site:
- Lymphocytic Leukemia, Chronic: A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Melbourne; Research Site:
- Lymphocytic Leukemia, Chronic: A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Sydney; Research Site:
- Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
Adelaide; Research Site:
- Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
Frankston; Research Site:
- Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
Fremantle; Research Site:
- Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
Melbourne; Research Site:
- Lymphoma, B-Cell: A Study of Avastin (Bevacizumab) in Combination With MabThera (Rituximab) and CHOP Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.
Woolloongabba; Research Site:
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Waratah, NSW; Newcastle Melanoma Unit
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Nedlands; Sir Charles Gairdner Hospital
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
Wodonga, Vic; Murray Valley Private Hospital and Cancer Treatment Center
- Malignant Melanoma: Phase III: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2 0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma
South Brisbane, Qld; Mater Adult Hospital
- Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Brisbane; Research Site:
- Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Melbourne; Research Site:
- Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Parkville; Research Site:
- Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Perth; Research Site:
- Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Sydney; Research Site:
- Mantle Cell Lymphoma: A Study of MabThera (Rituximab) for Treatment of Mantle Cell Non-Hodgkin's Lymphoma After Bone Marrow or Blood Stem Cell Transplantation
Woolloongabba; Research Site:
- Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Adelaide, South Australia; Medical Oncology
- Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Fremantle; Fremantle Hospital
- Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Hobart, Tasmania; Royal Hobart Hospital
- Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Lismore, NS; Lismore Base Hospital, Cancer Care & Haematology Unit
- Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Redcliffe; Redcliffe Hospital
- Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Waratah; Newcastle Melanoma Unit
- Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Wollongong; Clinical Trials
- Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Wooloongabba; Princess Alexandra Hospital
- Metastatic Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Adelaide, South Australia; Medical Oncology
- Metastatic Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Fremantle, WA; Fremantle Hospital
- Metastatic Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Hobart, Tasmania; Royal Hobart Hospital
- Metastatic Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Lismore, NS; Lismore Base Hospital, Cancer Care & Haematology Unit
- Metastatic Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Redcliffe; Redcliffe Hospital
- Metastatic Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Waratah; Newcastle Melanoma Unit
- Metastatic Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Wollongong; Clinical Trials
- Metastatic Melanoma: STA-4783 With Paclitaxel versus Paclitaxel Alone in Melanoma
Wooloongabba; Princess Alexandra Hospital
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Adelaide; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Ballarat; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Brisbane; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Canberra; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Darlinghurst; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Fitzroy; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Frankston; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Fremantle; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Geelong; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Gosford; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Heidelberg; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Hobart; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Melbourne; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Newcastle; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Parkville; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Perth; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
St. Leonards; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Sydney; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Townsville; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Wodonga; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Wollongong; Research Site:
- Non-Hodgkin's Lymphoma: A Study of MabThera (Rituximab) in Combination With a Standard Chemotherapy Regimen in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Woolloongabba; Research Site:
- Non-Hodgkin's Lymphoma: A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
Melbourne; Research Site:
- Non-Hodgkin's Lymphoma: A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
Perth; Research Site:
- Non-Hodgkin's Lymphoma: A Study of Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)
Woolloongabba; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Brisbane; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Liverpool; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Perth; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
South Brisbane; Research Site:
- Non-Hodgkin's Lymphoma: MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Wollongong; Research Site:
- Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Herston, QLD; Research Site
- Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
South Brisbane QLD; Research Site
- Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Woodville South SA; Research Site
- Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Frankston, VIC; Research Site
- Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Darlinghurst, NSW; Research Site
- Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Perth; Research Site
- Non-Hodgkin's Lymphoma: The purpose of the study is to compare the clinical benefit of galiximab when given in combination with rituximab as compared with rituximab alone (given with a placebo) in follicular NHL. Safety and pharmacokinetics (PK) will also be evaluated.
Ashford, SA; Research Site
- Non-Small Cell Lung Cancer: A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
Brisbane; Research Site:
- Non-Small Cell Lung Cancer: A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
Chermside; Research Site:
- Non-Small Cell Lung Cancer: A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
Heidelberg; Research Site:
- Non-Small Cell Lung Cancer: A Pilot Study of FDG- and FLT PET in Patients With Non-Small Cell Lung Cancer Treated with Tarceva (Erlotinib).
Melbourne; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer.
Tugun; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Brisbane; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Chermside; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Geelong; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Malvern; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Melbourne; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Perth; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
St. Leonards; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Sydney; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Tugun; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Waratah; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Wodonga; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Adelaide; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Brisbane; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Canberra; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Melbourne; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Parkville; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Perth; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Sydney; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Tugun; Research Site:
- Non-Small Cell Lung Cancer: A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Wollongong; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Auchenflower; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Chermside; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Greenslopes; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Lismore; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Melbourne; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Parkville; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Randwick; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Richmond; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
St. Leonards; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Sydney; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Wodonga; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.
Wollongong; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Adelaide; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Fitzroy; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Geelong; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Melbourne; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
St. Leonards; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Waratah; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Adelaide; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Fitzroy; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Geelong; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Melbourne; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
St. Leonards; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Waratah; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
Geelong; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
Melbourne; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Campbelltown; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Liverpool; Research Site:
- Non-Small Cell Lung Cancer: A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Sydney; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Adelaide; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Brisbane; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Frankston; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Fremantle; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Geelong; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Malvern; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Melbourne; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Perth; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
St. Leonards; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sydney; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Tugun; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Waratah; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Wodonga; Research Site:
- Non-Small Cell Lung Cancer: An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Wollongong; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Melbourne; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
St. Leonards; Research Site:
- Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Sydney; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Adelaide; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Ballarat; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Brisbane; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Canberra; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Liverpool; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
St. Leonards; Research Site:
- Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Sydney; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Adelaide; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Heidelberg; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Melbourne; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
St. Leonards; Research Site:
- Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
Sydney; Research Site:
- Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Adelaide; Research Site:
- Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Brisbane; Research Site:
- Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Canberra; Research Site:
- Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Frankston; Research Site:
- Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Melbourne; Research Site:
- Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Perth; Research Site:
- Renal Cell Cancer: A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Sydney; Research Site:
- Sarcoma: A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
Adelaide; Research Site:
- Sarcoma: A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
Melbourne; Research Site:
- Sarcoma: A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
Sydney; Research Site:
- Sarcoma: A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.
Westmead; Research Site:
- Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Box Hill; Department Of Medical Oncology, Box Hill Hospital
- Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Coffs Harbour; Coffs Harbour Health Campus
- Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Newcastle; David Maddison Building
- Skin Cancer: Phase II Study in Patients With Untreated Unresectable Stage II or IV Melanoma Receiving Dacarbazine and Ipilimumab (MDX-010) vs. Dacarbazine With Placebo
Port Macquarie; Port Macquarie Base Hospital
Austria
| |
